DEA Proposes New Import, Export Restrictions for Mesocarb

The Drug Enforcement Administration is proposing to list mesocarb, a substance with stimulating properties marketed in Russia for treatment of attention deficit hyperactivity disorder that has no approved medical use and no known therapeutic application in the U.S., under schedule I of the Controlled Substances Act, it said in a notice published Aug. 11. “If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess), or propose to handle, mesocarb.” Comments are due by Oct. 12.